Survodutide vs Retatrutide: Dual vs Triple Agonist
Survodutide vs retatrutide: GLP-1/glucagon dual agonist vs GIP/GLP-1/glucagon triple agonist, trial status, and report links. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Survodutide (Boehringer Ingelheim) is a GLP-1 and glucagon receptor dual agonist in late-stage trials for obesity and MASH. Retatrutide (Eli Lilly) adds GIP to make a GIP/GLP-1/glucagon triple agonist, also in phase 3. Neither is approved as of this page. Cross-trial weight-loss numbers are not a head-to-head comparison. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the Retatrutide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
related peptides:
community guides:
More confessions from the archive
Community Q&A
- Is survodutide the same as retatrutide?
- No. Survodutide targets GLP-1 and glucagon; retatrutide targets GIP, GLP-1 and glucagon. Different companies, different molecules.
- Are they approved?
- Neither was approved at time of writing; both are in late-stage trials.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.